期刊文献+

化疗周期对埃克替尼一二线化疗耐药的表皮生长因子受体突变不明的非小细胞肺癌临床疗效分析 被引量:1

Effect of chemotherapy cycle on the clinical efficacy of unknown mutation of epidermal growth factor receptor in non-small cell lung cancer patients with resistant to Ectinib Ⅰ and Ⅱ chemotherapy
原文传递
导出
摘要 非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌的常见类型,占肺癌比例的85%。其中,超过50%的患者病理类型为非鳞状细胞癌[1-3]。除此之外,60%~70%的患者一经诊断即为晚期,大部分晚期或术后复发的患者已不适合手术和放疗,对于这类患者首选的治疗方式为以铂类为基础的化疗。一线化疗失败或疾病进展的患者会选择无交叉耐药的二线化疗方案。目前,对于二线化疗治疗失败的非鳞NSCLC患者,一般情况下,再也没有可以使用的有效化疗药物。
作者 张莉 易成凤 何源 李中亚 余河江 赵云峰 Zhang Li;Yi Chengfeng;He Yuan
出处 《中华肺部疾病杂志(电子版)》 CAS 2019年第5期612-615,共4页 Chinese Journal of Lung Diseases(Electronic Edition)
  • 相关文献

参考文献8

二级参考文献64

  • 1吴一龙,蒋国梁,廖美琳,周清华,陆舜,王绿化,张力,无.非小细胞肺癌孤立性转移处理共识[J].循证医学,2007,7(2):109-111. 被引量:23
  • 2Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500. 被引量:1
  • 3Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N EnglJ Med, 2004, 350(21): 2129-2139. 被引量:1
  • 4Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-smaU cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA, 2014, 311 (14): 1430-1437. 被引量:1
  • 5Villa C, Cagle PT, Johnson M, et al. Correlation of EGFR mutation status with predominant his tologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med, 2014. 被引量:1
  • 6Usuda K, Sagawa M, Motono N, et al. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev, 2014, 15(2): 657-662. 被引量:1
  • 7Fan X, Furnari FB, Cavenee WK, et al. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor ceils. IntJ Oncol, 2001, 18(5): 1023-1026. 被引量:1
  • 8Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer, 2010, 69(1): 110-115. 被引量:1
  • 9Wu M, Zhao J, Song SW, et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer, 2010, 67(3): 343-347. 被引量:1
  • 10Park JH, Lee SH, Keam B, et al. EGFR mutations as a predictive marker of cytotuxic chemotherapy. Lung Cancer, 2012,77(2): 433-437. 被引量:1

共引文献1887

同被引文献14

引证文献1

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部